Company news

PRF Technologies Ltd. news in 2023

PRF Technologies Ltd.'s news releases, calls and decks from 2023, newest first.

View company

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

December 25, 2023

PainReform Provides Business Update for the Third Quarter of 2023

November 14, 2023

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

September 10, 2023

PainReform Provides Business Update for the Second Quarter of 2023

August 9, 2023

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

July 18, 2023

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

July 13, 2023

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

July 11, 2023

PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

May 17, 2023

PainReform Provides Business Update for the First Quarter of 2023

May 14, 2023

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

April 30, 2023

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

March 27, 2023

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

March 15, 2023

PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery

March 13, 2023

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement

February 6, 2023

Decks in 2023